The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle cell disease and beta thalassemia have benefited from the experimental therapy and experienced only temporary and treatable side effects, the companies developing the treatment announced on Tuesday.
The two patients, enrolled in a pair of ongoing clinical trials, have been free from blood transfusions and disease symptoms for a relatively short time, but the encouraging data offer hope that genome editing might one day offer a safe, durable cure for both blood diseases.
The companies, CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals, have competition. Last June, a one-time gene therapy for beta thalassemia from Bluebird Bio secured approval in Europe, with a U.S. approval expected next year. Several other companies and academic scientists are also pursuing curative treatments for beta thalassemia and sickle cell disease based on genome editing or gene therapy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect